CS168036B2 - - Google Patents

Info

Publication number
CS168036B2
CS168036B2 CS4540A CS454073A CS168036B2 CS 168036 B2 CS168036 B2 CS 168036B2 CS 4540 A CS4540 A CS 4540A CS 454073 A CS454073 A CS 454073A CS 168036 B2 CS168036 B2 CS 168036B2
Authority
CS
Czechoslovakia
Application number
CS4540A
Other languages
Czech (cs)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CS168036B2 publication Critical patent/CS168036B2/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CS4540A 1972-07-01 1973-06-25 CS168036B2 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6630172A JPS5512435B2 (pl) 1972-07-01 1972-07-01

Publications (1)

Publication Number Publication Date
CS168036B2 true CS168036B2 (pl) 1976-05-28

Family

ID=13311838

Family Applications (1)

Application Number Title Priority Date Filing Date
CS4540A CS168036B2 (pl) 1972-07-01 1973-06-25

Country Status (15)

Country Link
US (1) US3925357A (pl)
JP (1) JPS5512435B2 (pl)
AT (1) AT325206B (pl)
AU (1) AU469986B2 (pl)
BE (1) BE801588A (pl)
CA (1) CA996548A (pl)
CH (1) CH573435A5 (pl)
CS (1) CS168036B2 (pl)
DE (1) DE2332840A1 (pl)
FR (1) FR2190414B1 (pl)
GB (1) GB1386566A (pl)
HU (1) HU166029B (pl)
NL (1) NL7308048A (pl)
PL (1) PL92969B1 (pl)
SE (1) SE402916B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522148U (pl) * 1978-07-29 1980-02-13
HRPK20110926B3 (hr) * 2001-02-24 2013-05-31 Boehringer Ingelheim Pharma Gmbh & Co.Kg. Derivati ksantina, njihova proizvodnja i upotreba kao lijekova
US20030171424A1 (en) * 2002-03-07 2003-09-11 Lin Ai J. Intravenous formulation of artelinic acid for treatment of severe and complicated malaria
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2873524C (en) 2006-05-04 2018-02-20 Boehringer Ingelheim International Gmbh A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN101784278A (zh) * 2007-08-17 2010-07-21 贝林格尔.英格海姆国际有限公司 用于治疗fab-相关的疾病的嘌呤衍生物
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
MX370599B (es) * 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011006713A (es) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Formas salinas de compuesto organico.
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
MX364651B (es) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1026793A (fr) * 1949-08-02 1953-05-04 American Cyanamid Co Procédé de préparation de sels de pénicilline
NL6803062A (pl) * 1967-03-10 1968-09-11
US3557094A (en) * 1968-01-05 1971-01-19 Pfizer & Co C Substituted alkyl esters of alpha-carboxy aryl penicillins
AT290728B (de) * 1968-09-28 1971-05-15 Takeda Chemical Industries Ltd Verfahren zur herstellung neuer penicilline

Also Published As

Publication number Publication date
BE801588A (fr) 1973-12-28
FR2190414A1 (pl) 1974-02-01
AU469986B2 (en) 1976-02-26
JPS5512435B2 (pl) 1980-04-02
DE2332840A1 (de) 1974-01-17
FR2190414B1 (pl) 1976-07-02
CA996548A (en) 1976-09-07
CH573435A5 (pl) 1976-03-15
JPS4925121A (pl) 1974-03-06
GB1386566A (en) 1975-03-12
US3925357A (en) 1975-12-09
SE402916B (sv) 1978-07-24
PL92969B1 (pl) 1977-04-30
AU5760073A (en) 1975-01-09
NL7308048A (pl) 1974-01-03
HU166029B (pl) 1974-12-28
AT325206B (de) 1975-10-10

Similar Documents

Publication Publication Date Title
JPS4925121A (pl)
JPS49103999A (pl)
CH1117573A4 (pl)
CH372773A4 (pl)
CH545878A (pl)
CH559604A5 (pl)
CH559630A5 (pl)
CH559988A5 (pl)
CH560562A5 (pl)
CH562099A5 (pl)
CH562118A5 (pl)
CH563482A5 (pl)
CH563702A5 (pl)
CH564677A5 (pl)
CH565070A5 (pl)
CH565381A5 (pl)
CH565412A5 (pl)
CH565454A5 (pl)
CH566281A5 (pl)
CH566586A (pl)
CH567794A5 (pl)
CH569196A5 (pl)
CH573691A5 (pl)
CH573703A5 (pl)
CH574054A5 (pl)